

# Jillian H Broadbear

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8780760/publications.pdf>

Version: 2024-02-01

62  
papers

1,053  
citations

394421

19  
h-index

454955

30  
g-index

62  
all docs

62  
docs citations

62  
times ranked

1160  
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on $\mu$ -opioid agonists in the mouse writhing assay. <i>Psychopharmacology</i> , 1994, 115, 311-319.	3.1	126
2	Modulation of anxiety behavior in the elevated plus maze using peptidic oxytocin and vasopressin receptor ligands in the rat. <i>Journal of Psychopharmacology</i> , 2012, 26, 532-542.	4.0	72
3	Self-administration of fentanyl, cocaine and ketamine: effects on the pituitary/adrenal axis in rhesus monkeys. <i>Psychopharmacology</i> , 2004, 176, 398-406.	3.1	70
4	Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test. <i>Psychopharmacology</i> , 2010, 210, 35-43.	3.1	59
5	Risky drug use and effects on sleep quality and daytime sleepiness. <i>Human Psychopharmacology</i> , 2015, 30, 356-363.	1.5	42
6	Corticotropin-Releasing Hormone Antagonists, Astressin B and Antalarmin: Differing Profiles of Activity in Rhesus Monkeys. <i>Neuropsychopharmacology</i> , 2004, 29, 1112-1121.	5.4	39
7	Receptor reserve and affinity of $\mu$ opioid agonists in mouse antinociception: correlation with receptor binding. <i>Life Sciences</i> , 1995, 57, 2113-2125.	4.3	38
8	Effects of modafinil on simulator driving and self-assessment of driving following sleep deprivation. <i>Human Psychopharmacology</i> , 2008, 23, 681-692.	1.5	33
9	Examining the role of oxytocin in the interoceptive effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") using a drug discrimination paradigm in the rat. <i>Addiction Biology</i> , 2011, 16, 202-214.	2.6	32
10	Missed diagnosis: The emerging crisis of borderline personality disorder in older people. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 1139-1145.	2.3	32
11	Borderline personality disorder and depressive disorder. <i>Australasian Psychiatry</i> , 2019, 27, 573-577.	0.7	32
12	BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism. <i>European Journal of Pharmacology</i> , 2005, 509, 117-125.	3.5	28
13	Avoiding Misdiagnosis When Auditory Verbal Hallucinations Are Present in Borderline Personality Disorder. <i>Journal of Nervous and Mental Disease</i> , 2019, 207, 1048-1055.	1.0	25
14	Self-administration of methohexital, midazolam and ethanol: effects on the pituitary/adrenal axis in rhesus monkeys. <i>Psychopharmacology</i> , 2005, 178, 83-91.	3.1	23
15	Ecstasy use and self-reported disturbances in sleep. <i>Human Psychopharmacology</i> , 2011, 26, 508-516.	1.5	23
16	Noncontingent and Response-Contingent Intravenous Ethanol Attenuates the Effect of Naltrexone on Hypothalamic-Pituitary-Adrenal Activity in Rhesus Monkeys. <i>Alcoholism: Clinical and Experimental Research</i> , 2004, 28, 566-571.	2.4	21
17	Oxytocinergic regulation of endogenous as well as drug-induced mood. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 119, 61-71.	2.9	21
18	Antalarmin, a putative CRH-R1 antagonist, has transient reinforcing effects in rhesus monkeys. <i>Psychopharmacology</i> , 2002, 164, 268-276.	3.1	20

#	ARTICLE	IF	CITATIONS
19	Structural Determinants of Opioid Activity in Derivatives of 14-Aminomorphinones:Â Effect of Substitution in the Aromatic Ring of Cinnamoylaminomorphinones and Codeinones. Journal of Medicinal Chemistry, 2006, 49, 5333-5338.	6.4	20
20	What is the clinical significance of chronic emptiness in borderline personality disorder?. Australasian Psychiatry, 2018, 26, 88-91.	0.7	20
21	3-Alkyl Ethers of Clocinnamox:Â Delayed Long-Term $\frac{1}{4}$ -Antagonists with Variable $\frac{1}{4}$ Efficacy. Journal of Medicinal Chemistry, 1998, 41, 3493-3498.	6.4	19
22	Male and female ecstasy users: Differences in patterns of use, sleep quality and mental health outcomes. Drug and Alcohol Dependence, 2013, 132, 223-230.	3.2	17
23	An exploration of self-compassion and self-criticism in the context of personal recovery from borderline personality disorder. Australasian Psychiatry, 2019, 27, 56-59.	0.7	17
24	Long-Term Antihyperalgesic and Opioid-Sparing Effects of 5-Day Ketamine and Morphine Infusion (â€œBurst Ketamineâ€) in Diabetic Neuropathic Rats. Pain Medicine, 2015, 16, 1781-1793.	1.9	14
25	Sex differences in the pituitary-adrenal response following acute antidepressant treatment in sheep. Psychopharmacology, 2004, 171, 450-457.	3.1	13
26	14 $\frac{1}{2}$ -O-Cinnamoylnaltrexone and Related Dihydrocodeinones are Mu Opioid Receptor Partial Agonists with Predominant Antagonist Activity. Journal of Medicinal Chemistry, 2009, 52, 1553-1557.	6.4	12
27	Coronersâ€™ investigations of suicide in Australia: The hidden toll of borderline personality disorder. Journal of Psychiatric Research, 2020, 129, 241-249.	3.1	12
28	Reviewing the clinical significance of â€œfear of abandonmentâ€ in borderline personality disorder. Australasian Psychiatry, 2019, 27, 60-63.	0.7	11
29	6N-Cinnamoyl- $\frac{1}{2}$ -naltrexamine and its p-nitro derivative. High efficacy $\frac{1}{2}$ -opioid agonists with weak antagonist actions. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 167-172.	2.2	10
30	Acute MDMA administration alters the distribution and circadian rhythm of wheel running activity in the rat. Brain Research, 2010, 1359, 128-136.	2.2	10
31	Cinnamoyl Derivatives of 7 $\frac{1}{2}$ -Amino- and 7 $\frac{1}{2}$ -(Aminomethyl)-N-(cyclopropylmethyl)-6,14-endo-ethanotetrahydronoropavines are High-Potency Opioid Antagonists. Helvetica Chimica Acta, 2000, 83, 3122-3130.	1.6	8
32	Fumaroylamino-4,5-epoxymorphinans and Related Opioids with Irreversible $\frac{1}{4}$ Opioid Receptor Antagonist Effects. Journal of Medicinal Chemistry, 2012, 55, 9868-9874.	6.4	8
33	Ecstasy and sleep disturbance: Progress towards elucidating a role for the circadian system. Sleep and Biological Rhythms, 2012, 10, 3-13.	1.0	8
34	Consumer perspectives on personal recovery and borderline personality disorder. Journal of Mental Health Training, Education and Practice, 2017, 12, 350-359.	0.7	8
35	Opioid agonist effects on mouse writhing after irreversible mu receptor blockade with clocinnamox.. Experimental and Clinical Psychopharmacology, 1995, 3, 323-329.	1.8	7
36	Antidepressants, sex steroids and pituitary/adrenal response in sheep. Psychopharmacology, 2004, 175, 247-55.	3.1	7

#	ARTICLE	IF	CITATIONS
37	14 $\beta$ -Arylpropionylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and Related Opioids. Further Examples of Pseudoirreversible $\mu$ Opioid Receptor Antagonists. Journal of Medicinal Chemistry, 2009, 52, 6926-6930.	6.4	7
38	Potential Irreversible Ligands for Opioid Receptors. Cinnamoyl Derivatives of $\mu$ -Naltrexamine. Journal of Pharmacy and Pharmacology, 2011, 48, 192-196.	2.4	7
39	Clinician perspectives on recovery and borderline personality disorder. Journal of Mental Health Training, Education and Practice, 2017, 12, 199-209.	0.7	7
40	Developments in diagnosis and treatment of people with borderline personality disorder. Current Opinion in Psychiatry, 2020, 33, 441-446.	6.3	7
41	Glucocorticoid-reinforced responding in the rhesus monkey. Psychopharmacology, 1999, 147, 46-55.	3.1	6
42	Role of Sex and Sex Steroids in Mediating Pituitary-Adrenal Responses to Acute Buspirone Treatment in Sheep. Journal of Neuroendocrinology, 2005, 17, 051017082542002.	2.6	6
43	Corticotropin-releasing hormone in nonhuman primates. Frontiers in Bioscience - Landmark, 2006, 11, 2303.	3.0	6
44	Evaluation of a novel risk assessment method for self-harm associated with Borderline Personality Disorder. Australasian Psychiatry, 2017, 25, 460-465.	0.7	6
45	Pharmacokinetic comparison of a combination tablet of enalapril and hydrochlorothiazide with enalapril and hydrochlorothiazide tablets administered together and separately. Biopharmaceutics and Drug Disposition, 1991, 12, 447-455.	1.9	5
46	Dysfunctional overnight memory consolidation in ecstasy users. Journal of Psychopharmacology, 2014, 28, 751-762.	4.0	5
47	Emergency department utilisation by patients with a diagnosis of borderline personality disorder: An acute response to a chronic disorder. EMA - Emergency Medicine Australasia, 2022, 34, 731-737.	1.1	5
48	Role of metabolic risk factors in cardiovascular prognosis of systemic hypertension. American Journal of Cardiology, 1990, 65, H43-H45.	1.6	4
49	Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users. Journal of Psychopharmacology, 2009, 23, 759-774.	4.0	4
50	Evaluation of changes in prescription medication use after a residential treatment programme for borderline personality disorder. Australasian Psychiatry, 2016, 24, 583-588.	0.7	4
51	MDMA induces Per1, Per2 and c-fos gene expression in rat suprachiasmatic nuclei. Psychopharmacology, 2012, 220, 835-843.	3.1	3
52	Guest editorial. Pharmacology Biochemistry and Behavior, 2014, 119, 1-2.	2.9	3
53	The impact of COVID-19 lockdown on the well-being of clients of a specialist personality disorder service. Australasian Psychiatry, 2022, 30, 235-238.	0.7	3
54	Ten-week Intensive Group Program (IGP) for borderline personality disorder: making the case for more accessible and affordable psychotherapy. Evidence-Based Mental Health, 2021, 24, e1-e1.	4.5	2

#	ARTICLE	IF	CITATIONS
55	Disjunction in the subjective and objective measurement of co-occurring depression in borderline personality disorder – Implications for diagnosis. <i>Australasian Psychiatry</i> , 2022, 30, 481-485.	0.7	2
56	Disturbed sleep in ecstasy users reported by partners/roommates. <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 587-588.	2.3	1
57	Confidence of psychiatry trainees in meeting the needs of borderline personality disorder in comparison with schizophrenia. <i>Australasian Psychiatry</i> , 2021, 29, 103985622199265.	0.7	1
58	Discriminative stimulus properties of the 5-HT1A receptor biased agonists NLX-101 and F13714, in rats trained to discriminate 8-OH-DPAT from saline. <i>Behavioural Pharmacology</i> , 2021, Publish Ahead of Print, 652-659.	1.7	1
59	Assessment of peer-conceptualised, written and led single-session group interventions for carers supporting a person with borderline personality disorder. <i>Advances in Mental Health</i> , 0, , 1-12.	0.7	1
60	Hallucinations in BPD: More prevalent than community sample study suggests?. <i>British Journal of Psychiatry</i> , 2017, 211, 250-251.	2.8	0
61	Editorial: Preface and Overview Second International MDMA –Ecstasy™ Conference in Australasia: Monash University, Melbourne, Australia. <i>The Open Addiction Journal</i> , 2011, 4, 1-3.	0.5	0
62	The impact of COVID-19 lockdown on the well-being of mental healthcare providers working in a specialist clinic for personality disorder. <i>Australian Psychologist</i> , 0, , 1-7.	1.6	0